Skip to content

Author

Y. Fahfouhi

We have 2 of 19 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Quantifying the societal benefits of adult immunization against respiratory diseases in France: a benefit cost analysis.

France's adult respiratory vaccination programs generate positive socioeconomic returns and including adult RSV vaccination and increasing vaccination uptake would further increase their societal benefits.

Matthew Napier, S. Brassel, E. Tunnicliffe et al. · 0 citations
Open access Aug 2026

A health-economic assessment of the impact of different RSVpreF maternal vaccine strategies to prevent RSV infections among young infants, in France: EPIPACT.

OBJECTIVES Most of the clinical and economic burden of the respiratory syncytial virus (RSV) in pediatric populations is concentrated among infants aged <1 year. Since 2024, RSVpreF vaccine is available in France for the vaccination of pregnant women between 32 and 36 weeks of gestational age, from September to January...

Y. Fahfouhi, S. Fiévez, R. Cohen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.